Nebenwirkungen · Ferriprox
Ferriprox 100 mg/ml oral solution · Abschnitt 4.8 · PDF-Seite 20
HOS-089854 · Präparat HOS-083927
The most common adverse reactions reported during therapy with deferiprone in clinical studies were nausea, vomiting, abdominal pain, and chromaturia, which were reported in more than 10% of patients. The most serious adverse reaction reported in clinical studies with deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5x109/l, which occurred in approximately 1% of patients. Less severe episodes of neutropenia were reported in approximately 5% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-21T02:00:00Z · SHA-256 8d30ff208e2cac65daccef3e0bb072261a28975145087d11012d5a853f6fab1e · Passage 932fdd199c70afbb6d3d36fffb3e2956675bbcafc3275cad92fe2bee49294078 · Zeichen 31–524 im Abschnitt